Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Hims & Hers management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Read why HIMS ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

A post-earnings rally in Hims & Hers Health Inc. has turned co-founder and Chief Executive Officer Andrew Dudum into a weight-loss billionaire.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Novo Nordisk (NVO) stock rises after Q1 2025 results, even after the company cut its outlook as it sees a sales recovery for ...

A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will ...

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...